Xenetic Biosciences Inc (XBIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Xenetic Biosciences Inc (XBIO) has a cash flow conversion efficiency ratio of -0.166x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-658.25K) by net assets ($3.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Xenetic Biosciences Inc (XBIO) net asset quality to measure how much of total assets are equity-financed.
Xenetic Biosciences Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Xenetic Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Xenetic Biosciences Inc (XBIO) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Xenetic Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xenetic Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Solteq PLC
HE:SOLTEQ
|
-0.024x |
|
Austchina Holdings Ltd
AU:AUH
|
-0.034x |
|
Northern Shield Resources Inc.
V:NRN
|
-0.115x |
|
ARK Resources Bhd
KLSE:7007
|
0.256x |
|
ESE Entertainment Inc
V:ESE
|
-0.052x |
|
Union Pioneer Public Company Limited
BK:UPF
|
-0.058x |
|
Teamo Productions HQ Limited
NSE:TPHQ
|
0.148x |
|
Nandani Creation Limited
NSE:JAIPURKURT
|
-0.166x |
Annual Cash Flow Conversion Efficiency for Xenetic Biosciences Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Xenetic Biosciences Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Xenetic Biosciences Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $6.01 Million | $-2.82 Million | -0.469x | -11.67% |
| 2023-12-31 | $9.80 Million | $-4.11 Million | -0.420x | -23.35% |
| 2022-12-31 | $13.65 Million | $-4.65 Million | -0.340x | -32.19% |
| 2021-12-31 | $18.39 Million | $-4.74 Million | -0.258x | +26.26% |
| 2020-12-31 | $12.22 Million | $-4.27 Million | -0.349x | +6.04% |
| 2019-12-31 | $17.21 Million | $-6.40 Million | -0.372x | +42.99% |
| 2018-12-31 | $9.91 Million | $-6.46 Million | -0.652x | -724.13% |
| 2017-12-31 | $14.30 Million | $1.49 Million | 0.104x | +119.23% |
| 2016-12-31 | $16.17 Million | $-8.79 Million | -0.543x | +32.25% |
| 2015-12-31 | $6.61 Million | $-5.30 Million | -0.802x | +31.82% |
| 2014-12-31 | $10.48 Million | $-12.33 Million | -1.176x | -145.26% |
| 2013-12-31 | $12.62 Million | $-6.05 Million | -0.480x | -59.16% |
| 2012-12-31 | $20.78 Million | $-6.26 Million | -0.301x | -- |
About Xenetic Biosciences Inc
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, a… Read more